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Should African Americans be overtreated for
depression the same as whites are?
Commentary on Waldman et al (2009)
Contrary to the interpretation that Waldman et al
1
provide, we believe that their data point to carelessness
with which antidepressants (ADs) are currently being
prescribed to both African Americans and whites. These
authors examined charts of 864 of 8,028 available
patients who had undergone left heart cardiac catheter-
ization. Apparently, records of AD prescriptions and self-
report depression inventories were available, but no
formal diagnoses of depression. Furthermore, data were
available for only 137 African American patients, with
only 16 of them receiving an AD. Multivariate regression
and subgroup analyses are thus not valid.
2
The authors report that 27% of the sample had
elevated scores (≥10) on the depression inventory and
that an additional 10% of the patients with lower scores
on the depression inventory received an AD. From these
figures, the authors infer that 38% of the sample had
significant depression. However, an elevated score on a
self-report depression scale is not itself an indication of
the need for AD treatment. In fact, between one tenth
and one fifth of patients with scores ≥10 would be found
to have major depression,
3 suggesting a much lower
estimate of the patients appropriate to receive antide-
pressants. There is thus evidence of gross nonspecific
prescribing and overtreatment with ADs in this sample.
That 10% of the sample with low depression scores have
received an AD is also troubling. Given the poor quality of
routine care for depression in general medical settings
4
and modest reductions in depression this care is likely to
yield,
2 it is unlikely that many of these patients were
depressed when prescribed an AD or that their low
depression scores represent a reduction in symptoms.
Undoubtedly, much depression in medical patients
remains undetected and undertreated, but the problem
of AD overtreatment is substantial and growing.
5
Perhaps, steps could be made to ensure that African
Americans have greater access to overtreatment and
poor quality depression care. However, we believe it
would be much more important that better quality,
more nuanced data than what were mustered by
Waldman should be gathered to identify breakdowns in
the delivery of appropriate prescription of AD and
adequacy of follow-up care for depression among all
patients, white and minority.
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